BG-9928 (Biogen Idec).
Biogen Idec, under license from CV Therapeutics, is developing BG-9928, a selective oral adenosine A, receptor antagonist, for the potential treatment of congestive heart failure. By January 2003, phase II trials of BG-9928 were ongoing.
Doggrell
Sheila A
SA
Division of Health Practice, Auckland University of Technology-Akoranga Campus, Auckland, New Zealand. sdoggrell@xtra.co.nz
D058916:Adenosine A1 Receptor Antagonists; D000818:Animals; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D013329:Structure-Activity Relationship; D014970:Xanthines / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
D058916:Adenosine A1 Receptor Antagonists; C505954:BG 9928; D004232:Diuretics; D014970:Xanthines